Last checked at 27 Apr 2018 14:00
For immediate release 2.00pm: 27 April 2018
HVIVO PLC
("hVIVO" or the "Company")
2017 Annual Report and Financial Statements
hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, is pleased to announce that its Annual Report and Financial Statements for the year ended 31 December 2017 is being posted to shareholders today.
It will be available on the Company's website (http://hvivo.com/investors/financial-reports/) from 4.30 pm today.
For further information please contact:
hVIVO plc | |
Trevor Phillips (Executive Chairman) | +44 207 756 1300 |
Fleur Wood (Director, Investor Relations)
|
|
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.